Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations

Biol Blood Marrow Transplant. 2014 Jul;20(7):908-19. doi: 10.1016/j.bbmt.2014.02.013. Epub 2014 Feb 22.


Hematopoietic stem cell transplantation (HSCT) is a potentially life-saving therapy that has traditionally been associated with high treatment-related mortality due to direct regimen toxicity and a high incidence of graft-versus-host disease. Historically, pre-existing renal insufficiency has been considered an exclusion criterion for transplantation. The advent of nonmyeloablative conditioning regimens as a less toxic modality for treatment has made HSCT more accessible to elderly patients and patients with comorbidities, such as renal impairment. However, there is no clear standard for how to dose preparative regimens for patients with chronic renal impairment who undergo HSCT. This article serves as a review of the current literature to provide dosing recommendations for commonly used preparative agents in the setting of chronic kidney disease, with the aim of providing optimal dosing for this patient population.

Keywords: Dosing; Hematopoietic cell transplantation; Preparative regimens; Renal insufficiency.

Publication types

  • Review

MeSH terms

  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Renal Insufficiency, Chronic / therapy*
  • Transplantation Conditioning / methods*
  • Transplantation, Homologous